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De-escalation trials are challenging and sometimes may fail due to poor recruitment.  The OPTIMA 
prelim randomised controlled trial (RCT) (ISRCTN42400492) randomised patients with early stage 
breast cancer to chemotherapy versus ‘test-directed’ chemotherapy, with a possible outcome of no 
chemotherapy which could confer less treatment relative to routine practice.  Despite encountering 
challenges, OPTIMA prelim reached its recruitment target ahead of schedule. This study reports the 
root-causes of recruitment challenges and strategies employed to successfully overcome them. 
Materials and Method 
A mixed-methods recruitment intervention (‘QuinteT Recruitment Intervention’, QRI) was employed 
to investigate the recruitment difficulties and feed-back findings to inform interventions and 
optimise ongoing recruitment.  Quantitative site-level recruitment data, audio-recorded recruitment 
appointments (n=46), qualitative interviews (n=22) with trialists/recruiting staff (oncologists/nurses) 
and patient-facing documentation were analysed using descriptive, thematic, and conversation 
analyses.  Findings were triangulated to inform a ‘plan of action’ to optimise recruitment.  
Results 
Despite best intentions, oncologists’ routine practices complicated recruitment.  Discomfort about 
deviating from the usual practice of recommending chemotherapy according to tumour 
clinicopathologic features, meant that not all eligible patients were approached.  Audio-recorded 
recruitment appointments revealed how routine practices undermined recruitment.  A tendency to 
justify chemotherapy provision before presenting the RCT, and subtly indicating that chemotherapy 
would be more/less beneficial undermined equipoise and made it difficult for patients to engage 
with OPTIMA prelim.  To tackle these challenges, individual and group recruiter feedback focussed 
on communication issues, and vignettes of eligible patients were discussed to address discomforts 
around approaching patients.  ‘Tips’ documents concerning structuring discussions and conveying 
equipoise were disseminated across sites, alongside revisions to the Patient Information Sheet.   
Conclusions 
This is the first study illuminating the tension between oncologists’ routine practices and 
recruitment to de-escalation trials. Although time and resource is required, these challenges can be 
addressed through specific feedback and training as the trial is underway.  
 




Multi-parameter tumour gene expression assays (MPAs) have driven new approaches to adjuvant 
chemotherapy decision-making for breast cancer [1-3].  The UK’s National Institute for Health and 
Care Excellence (NICE) has approved use of several MPAs to guide adjuvant chemotherapy decisions 
in patients with oestrogen receptor positive (ER+), human epidermal growth factor receptor 2 
negative (HER2−) lymph node negative breast cancer.  Whilst there is potential to extend this 
recommendation to node-positive patients, NICE has called for robust randomised controlled trial 
(RCT) evidence to inform future guidance [4].  For more than 50 years, RCTs have been driving 
important developments in the treatment of breast cancer [5-7], but recruitment issues have 
threatened the timely and successful completion of trials [8, 9].  This is particularly true of de-
escalation of treatment studies, which have come to the fore in early breast cancer research in 
recent years [10].  Reported obstacles have included logistical issues, lack of eligible patients, limited 
research resources, and patient preferences for/against treatments [11].  Research has revealed a 
number of challenges for recruiters, including the emotional burden of recruitment, lack of 
equipoise and reconciling the roles of clinician and researcher [12, 13].  
The OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) 
trial [14, 15] is a UK-based multicentre clinical trial that randomises patients to adjuvant 
chemotherapy (current care) versus ‘test-directed’ adjuvant chemotherapy or ‘no chemotherapy’.  
OPTIMA is designed to demonstrate non-inferiority of this approach to patient outcome, particularly 
for those with node-positive disease.  OPTIMA prelim was the feasibility phase of the study and was 
designed to demonstrate the acceptability of a large-scale trial of MPA-directed treatment to 
patients and clinicians.  An overview of OPTIMA prelim is reported in full elsewhere [15, 16] and 
included in Appendix 1.  The OPTIMA prelim trial management group (TMG) anticipated that 
recruitment would be difficult, as many patients who would be offered chemotherapy in current UK 
practice, would be allocated to ‘no chemotherapy’ within the trial. The TMG therefore integrated 
the ‘QuinteT Recruitment Intervention’ (QRI) [17] into the RCT protocol.  This is a complex 
intervention that aims to identify and understand sources of recruitment difficulty rapidly, and then 
develop strategies to address these throughout the remainder of the trial.  An evaluation of the 
effectiveness of the QRI approach using before and after data for several trials, including OPTIMA 
prelim, has been published elsewhere [18].  
This article reports on the sources of recruitment difficulty in this challenging trial and the specific 
strategies implemented to try and overcome these.   
 
Method and Materials  
Design  
This paper reports a mixed-methods study using the QRI [17, 19] to understand and address 
recruitment issues. The QRI consisted of two iterative phases. Phase 1 aimed to understand 
recruitment obstacles rapidly, using mixed (predominantly qualitative) methods. Phase 2 involved 
working collaboratively with the Chief Investigator (CI) and TMG to devise and deliver tailored 
strategies to address recruitment difficulties, based on evidence from Phase 1.  
The QRI was integrated within the study protocol; ethical approval was granted by the South East 
Coast–Surrey Research Ethics Committee (12/LO/0515, 22 June 2012).  
QRI Phase 1: Understanding recruitment obstacles 
Phase 1 began when recruitment had started.  All sites open at the time (n=25) were invited to take 
part, nine agreed to participate in one or more aspects of the data collection discussed below.  
Key informants, including oncologists, research nurses, and TMG members, were purposefully 
sampled for interview based on their role in overseeing or conducting recruitment.  32 staff were 
invited to participate in in-depth semi-structured interviews about their perspectives on 
recruitment.  Interviews were conducted face-to-face or via telephone (by LR and JLD) and lasted 
between 40 - 90 minutes. Research nurses were also approached to take part in shorter, structured 
interviews regarding the operation of recruitment processes at their sites.  Sampling for interviews 
concluded when data saturation was reached (i.e. when no new issues arose from two consecutive 
interviews).  
Recruiting staff (oncologists and research nurses) were asked to routinely audio-record discussions 
concerning OPTIMA prelim with eligible patients (“recruitment appointments”) including when they 
accepted or declined trial participation.  Initial verbal and subsequent written patient consent was 
obtained for all audio-recordings.   
All interviews and audio-recorded appointments were analysed thematically using the constant 
comparative method derived from grounded theory methodology [21]. In addition, techniques 
adapted from conversation analysis [22] were used to examine the structure and sequencing of 
interactions. All transcripts of interviews/appointments were analysed by one researcher using the 
above techniques (LR). To enhance reliability, another researcher (SP) analysed 10% of interviews 
and appointments in the early stages of data collection, with semantic differences in coding 
discussed and resolved. Going forwards, key findings and interpretations from the analysis were 
interrogated by the study team (LR, SP, JD) through testing claims with raw data and discussing in 
regular meetings. Finally, a new researcher (CC) joined the team once data collection was complete 
and listened to all audio-recorded consultations and reviewed interview transcripts/coding, with a 
view to agreeing the core messages pertaining to this paper with LR and JD. 
The data collection techniques were supplemented with content analysis of patient-facing 
documentation and descriptive analyses of recruitment screening logs.  Screening logs were 
regularly assessed to summarise the numbers of patients recorded as eligible and the proportion of 
those who accepted/declined an invitation to participate.  Figures were compared over time and 
across sites. 
QRI Phase 2: Developing and delivering a ‘plan of action’ to optimise recruitment. 
Data and emerging findings from the analyses were considered in tandem to triangulate data and 
crystalize the key issues that appeared to be undermining recruitment.  These issues were reported 
to the CI /TMG and informed a ‘plan of action’ to optimise recruitment.  A statistical evaluation of 
the impact of these strategies on recruitment has been reported elsewhere [18]. 
Results  
Phase 1: Understanding recruitment obstacles 
Early in the recruitment phase, fourteen semi-structured interviews were conducted with TMG 
members and oncologists from six sites whilst eight research nurses took part in structured 
interviews.  The interviews were conducted with staff from sites considered ‘mid-range’ in terms of 
recruitment rates (recruiting 0.32 to 1.85 patients per month, compared with a range of 0 to 2.20 in 
the overall trial).  Between November 2012 and January 2014 46 appointments were audio-recorded 
involving 11 oncologists and 29 patients (Table 1).  The audio-recordings and interviews were 
obtained from recruiting sites from Scotland, and the South West, South East, and Midlands regions 
of England.   







Audio-recordings of recruitment discussions 
between oncologists and patients  







Site 1 1 oncologist* 
1 surgeon 
1 research nurse  
4  2 1 oncologist 
Site 2  1 oncologist* 23  11 4 oncologists 
Site 3  4 oncologists 
1 research nurse  
7  5  2 oncologists 
Site 4  0 6 5 1 oncologist 
Site 5  0 4 4 2 oncologist 




2 research nurses,  
1 trial manager 
NA NA NA 
Total 14 46 29 11 
* Member of the Trial Management Group  
Challenges to recruitment  
Analysis of interviews highlighted that oncologists were generally very committed to OPTIMA’s 
endeavour of better targeting as to which patients benefited from chemotherapy provision, and 
often emphasised the need for evidence-based approaches to reduce the burden of over-treatment.  
Despite this enthusiasm, difficulties arose at two key points of the recruitment process: approaching 
eligible patients and discussing OPTIMA prelim in recruitment appointments.  
Approaching eligible patients 
Discomfort with aspects of the eligibility criteria, coupled with some hesitancy about the accuracy of 
multi-parameter testing, resulted in some eligible patients not being approached about trial 
participation. Oncologists and other members of the multi-disciplinary team (MDT) had variable 
thresholds of comfort regarding different aspects of the eligibility criteria associated with risk of 
recurrence. This was particularly evident in relation to patients’ nodal status. The eligibility criteria 
allowed for patients with up to 9 involved lymph nodes to be included in the study, but oncologists’ 
individual thresholds for permitted nodal involvement varied. (See Box 1, Extracts 1). 
Some oncologists took into account tumour characteristics and criteria not specified in the trial 
protocol in their judgements of who to approach for the trial. These were criteria that they would 
usually consider in treatment-decisions in routine practice where MPA testing was not normally 
available. For example, some oncologists were reluctant to approach patients with grade 3 tumours, 
on the basis that they felt these individuals would require chemotherapy (Box 1, Extract 2).  
Assessments about patients’ emotional state also factored into decisions about approaching eligible 
patients. Some oncologists and research nurses described instances where patients had been 
deemed eligible by the MDT but were not approached because of how they presented emotionally 
at their appointment, and other instances where patients were approached with hesitancy (Box 1, 
Extract 3), based on judgments about their ability to cope with trial participation decisions.  
 
Box 1 Interview extracts  
 
Extract 1 - The only thing that surprised me with the criteria is the lymph node status; one, because 
it’s almost ingrained in our practice and certainly as oncology trainees as we go through doing the 
exams and so on, that lymph node positivity is a risk factor for a recurrence, and that those 
patients who are highest risk, benefit from chemotherapy most. (Oncologist site 4)  
 
Extract 2 - I think people feel very uncomfortable about letting heavily node positive Grade 3 
disease [into the trial]… there’s something about - they strongly feel those patients need chemo, 
and the idea that they might go into a trial where they’re not being given chemo makes them feel 
very uncomfortable.  (Oncologist site 2) 
 
Extract 3 - So we might, if we thought they weren’t really suitable, we might say “Well, we do have 
a trial that would help us to choose whether to have chemotherapy or not and would you like us to 
explain that to you?” in a kind of very general way, and kind of probably hoping that the patient 
will say “No, I don’t want anything like….oh no I don’t want that.”  (Research nurse site 2) 
 
Extract 4 - “Well I think it’s quite important not to [respond to a patient preference], it has the 
potential to kind of damage the relationship with the patient because the patient then feels, 
there’s risk that they might feel they’re letting you down,” (Oncologist site 2) 
 
 
Discussing OPTIMA prelim in Recruitment Appointments  
The audio-recorded recruitment discussions revealed how oncologists’ communication practices 
could undermine trial recruitment, despite their best intentions to recruit.  Applying routine 
approaches to discussing adjuvant chemotherapy did not align with the trial’s premise, and created 
problems in some cases, as outlined below.  
Structure of Appointments and Conveying Chemotherapy Uncertainty 
All recruiters successfully mentioned uncertainty around the benefits of chemotherapy as part of the 
RCT rationale.  Oncologists generally used one of two approaches to structuring the discussion: 1) 
introducing chemotherapy as a beneficial treatment (as per routine practice), and then explaining 
the trial rationale; or 2) introducing the uncertainties around chemotherapy from the outset of the 
consultation, followed by an explanation of the trial.  The first approach sometimes coincided with 
patients settling on the idea of needing chemotherapy; to then introduce the idea that they may not 
benefit from chemotherapy and could potentially forego this in OPTIMA prelim, was therefore 
somewhat confusing (Box 2, Extract 1).  In contrast, opening the discussion with the uncertainties of 
chemotherapy benefit provided a smoother route to explaining the trial rationale (Box 2, Extract 2).  
 
Box 2 Recruitment appointment extracts  
 
Extract 1, site 2 
Onc: Back to drugs. The other thing that we have to consider, and it’s I would say a case of icing on 
the cake, but nevertheless, we should talk about it, is the benefits of a course of chemotherapy.  
Pat: Would you recommend it then? 
Onc: I think with what you have, there is probably enough benefit for it to be worthwhile. It should 
be considered quite seriously.  
[Later]  
Pat:  So without chemotherapy? 
Onc: There is a bigger risk that this comes back in the future. It’s not a huge risk, but it’s enough to 
make the benefits of chemotherapy worthwhile. 
Pat: Okay. I’ve got to do it then, haven’t I? 
Onc: There is a possible way out of this. [Introduces OPTIMA prelim and the Oncotype DX test].  
Pat: You’ve completely confused me now. OK, so I accept that I’ve got to have the chemotherapy 
and tablets . . . 
 
Extract 2, site 2 
Onc:  The thing that is a little harder to decide is whether you need chemotherapy or not. 
Pat: It’s the big one yeah. 
Onc:  It’s a harder decision for two reasons. One is, that it’s, lots of patients like yourself would be 
fine even if they didn’t have it, and also it has obviously more side effects [explains probability of 
benefit]. That means though that 90 of them or more who have had chemotherapy have had no 
benefit.  
Pat: It’s just whether I’m one of those ones. 
 
Extract 3, site 1 
Relative: ‘Cos – I know, before today, my wife had decided that she wasn’t going to go on the trial. 
Onc: OK. 
Pat: Um, purely because when I spoke to [Mr X, surgeon], my husband asked him what he’d do and 






Participation in OPTIMA prelim required patients to be happy (in principle) with the idea of being 
allocated ‘current care’ (chemotherapy) or test-directed treatment, which carried the possibility that 
they would not receive chemotherapy.  As recruiters, oncologists and research nurses needed to 
convey equipoise by finely balancing the advantages and disadvantages of each of the trial arms.  
One aspect that proved difficult was addressing uncertainty about the Oncotype DX test’s 
effectiveness, which underpinned the need for the trial.  Oncologists and research nurses discussed 
experiences of some patients opting to access the test outside the NHS and other patients not being 
comfortable with the uncertainty around the test.  Conveying the potential benefits and 
disadvantages of the test proved a delicate balancing act.   
 
Oncologists’ language during recruitment appointments had the potential to tip the balance towards 
or against test-directed treatment.  Some recruiters reverted to terms and phrases that would 
usually be helpful for explaining the rationale for chemotherapy (in routine practice), but this 
undermined the need to convey equipoise in the RCT context.  For example, referring to 
chemotherapy as ‘icing on the cake’ (Box 2, Extract 1) had potential to influence a patient’s 
perception of chemotherapy as a worthwhile treatment.   
Some oncologists continued their routine practice of referring to on-line predictor tools (e.g. 
PREDICTi and Adjuvant! Onlineii)  to demonstrate likely chemotherapy benefit to patients, despite the 
trial’s hypothesis that MPAs provide a superior framework for decision-making.  Some patients, who 
were shown the graphical representation of possible chemotherapy benefit interpreted this as 
definitive individual benefit for them, rather than the estimated population benefit these tools 
provide.   This contradicted the ethos of the trial, i.e. examining the effectiveness of MPAs as 
predictors for individual patient benefit.  
 
Addressing Patients’ Preferences and Expectations 
Oncologists and research nurses anticipated that patient preferences would be a barrier to 
recruitment, and often discussed this in terms of patients not wanting to forgo chemotherapy.  The 
audio-recorded appointments showed that when preferences were expressed, recruiters tended to 
cease discussion about the trial; their accounts in interviews often indicated concern about upsetting 
the clinician-patient relationship (Box 1, Extract 4). 
 
In such instances, patients’ perceptions (and potential misconceptions) about treatments were not 
addressed, resulting in missed opportunities to offer additional information patients might not have 
considered.  For example, in one appointment the patient was concerned about hair loss from 
chemotherapy, although this only arose after she had declined the RCT in favour of endocrine 
therapy alone.  The strategies that some other recruiters had used to try to inform patients about 
options available to address hair loss (e.g. cold capping, wigs) were not discussed in this instance.   
A key issue that was reported in interviews and apparent in some recordings was patients’ up-front 
expectations for chemotherapy.  Some patients reported that surgeons had referred to 
chemotherapy as advisable or the next step in their post-surgical treatment, reflecting the 
‘signposting’ that might be offered in routine practice.  In the context of OPTIMA prelim, however, 
this could make it very difficult for oncologists to explain the rationale for the trial (see Box 2, Extract 
3).    
Phase 2: Developing and delivering a ‘plan of action’ to optimise recruitment  
Issues arising from Phase 1 were first reported to the CI/TMG two months after the QRI started.  The 
QRI team worked with the TMG to co-produce a series of interventions to address recruitment 
challenges.  Table 2 details the interventions and the timing of their implementation alongside the 
issues they were designed to address.    
Table 2 OPTIMA prelim recruitment challenges and corresponding QRI interventions  
QRI Action Implemented Recruitment Issue Addressed 
Tips and guidance document circulated to all 
sites (October 2013) 
• Structuring the consultation 
• Explaining chemotherapy and its 
uncertainties 
• Talking about the test  
Revised Patient Information Sheet distributed 
to all sites (October 2013) 
• Convey more balanced portrayal of the 
advantages and disadvantages of test-
directed chemotherapy 
Group feedback: 
Scottish sites (November 2013)  
South West and Welsh sites (January 2014) 
Site 5 (March 2014)  
Site 6 (March 2014) 
• Identifying potentially eligible patients 
• Approaching eligible patients 
• Discussing the study in recruitment 
appointments (conveying uncertainty of 
chemotherapy, use of chemotherapy 
predictor tools, explaining trial concepts, 
probing patient preferences)  
Recruitment tips presented to newly opening 
sites (January 2014 onwards) 
• Explaining chemotherapy and its 
uncertainties 
Individual Recruiter Feedback to four 
oncologists (February – March 2014) 
• Discussing the study in recruitment 
appointments (as above) 
 
A ‘tips and guidance’ document was drafted and circulated to all sites and provided suggestions for 
structuring recruitment consultations, talking about the uncertain benefits of chemotherapy and 
discussing the Oncotype DX test (see the Appendix 2). The QRI researchers and TMG also revised the 
Patient Information Sheet to convey a clearer, more balanced portrayal of the advantages and 
disadvantages of using Oncotype DX to determine chemotherapy.   
Individual and group feedback were core components of the plan of action, enabling the QRI team to 
use anonymised extracts from interviews and audio-recorded appointments to illustrate key 
recruitment issues and facilitate discussion around clinician driven possible solutions.  Extracts from 
the interviews and audio-recorded appointments illuminated variable views about eligibility criteria 
and patient preferences, and the CI/TMG members contributed expert knowledge to elicit group 
discussion and engender peer-to-peer learning. At one session, the CI used clinical vignettes 
portraying patients at the margins of the eligibility criteria to tease out and address sources of 
discomfort. Group feedback sessions also covered issues around structuring consultations, use of 
language, and the subsequent ways in which these could influence patients’ interpretation of trial 
information.  In addition to these group sessions, oncologists who provided audio-recorded 
appointments received individual confidential feedback.  Issues discussed included structuring the 
recruitment discussion by opening with chemotherapy uncertainty, explaining the study rationale 
and design, and strategies for clearly explaining the Oncotype DX test and RCT concepts.   
Recruitment Outcomes 
OPTIMA Prelim exceeded its recruitment target, consenting 350 patients and randomising 313 
patients in 20 months against a target of 300 patients in 2 years. Having established its acceptability 
to patients and clinicians and secured funding, the main OPTIMA trial (with an integrated QRI) 
opened to recruitment in January 2017.  The study is currently recruiting from more than 100 sites 
across the UK and Norway.  
 
Discussion  
Our study used the QuinteT Recruitment Intervention to understand and address the challenges of 
recruiting to a de-escalation trial comparing routine with a novel approach to determining adjuvant 
chemotherapy provision in patients with early stage breast cancer.  Despite experiencing challenges, 
the recruitment target was eventually exceeded within the funded timescale through identifying and 
addressing the root-causes of recruitment difficulties in real-time.  We identified numerous ways in 
which oncologists’ routine practices could either subtly or sometimes overtly inhibit RCT 
recruitment.  There was evidence that some oncologists and MDTs gravitated towards offering the 
trial to a kernel of patients within the wider eligible population, avoiding those with clinical 
characteristics that they felt indicated a clear need for chemotherapy (e.g. greater lymph node 
involvement).  When patients were approached, terminology and tools typically used to discuss 
chemotherapy in routine practice were found to contradict the rationale for OPTIMA prelim and 
undermine recruitment.  To tackle these challenges, a series of interventions were implemented, 
including a tips and guidance document, individual and group feedback, and revisions to the Patient 
Information Sheet.  
This study illuminated how oncologists’ routine practices could inhibit recruitment at multiple stages 
of the recruitment process.  There was evidence that not all clinicians and/or MDTs felt comfortable 
offering the study to all groups of eligible patients, which if widespread and inconsistently done 
across sites, might threaten the external validity of the definitive trial results as applied to all 
potentially eligible patients [20].  Discomfort with and selective application of trial eligibility criteria 
have been observed in other RCTs, as reported in a cross-trial investigation of recruitment issues 
across six RCTs that spanned different medical specialties (including oncology, mental health, and 
surgery) [11, 12].  Airing and addressing these issues was central to the OPTIMA prelim ‘plan of 
action’.  Recruiters were encouraged to consider their own perceptions of equipoise through clinical 
vignettes in group feedback sessions, where they had an opportunity to reflect on their practice and 
that of their peers and discuss and share concerns.   
OPTIMA prelim demonstrated the challenges of negotiating ‘current best practices’ in routine care 
with the endeavour of improving future patients’ care through their role as trial recruiters. OPTIMA 
prelim and the main trial have potential to transform future practice, but this is counter-balanced 
with the possibility of significant consequences for current patients should the trial hypothesis not 
be supported. Furthermore, whilst accustomed to recruiting to trials exploring additional 
treatments, oncologists were less familiar recruiting to de-escalation trials [1, 21-24].  A growing 
body of work has focussed on tensions recruiters face when trying to negotiate their ‘clinical’ and 
‘research’ roles [11, 12, 20, 25], contributing to the often ‘hidden’ emotional and intellectual 
challenges of recruiting patients [12, 13]. Being mindful of the potential challenges and pitfalls of 
implementing trial eligibility criteria, may help clinical investigators plan for and identify these issues 
more readily.  Examining and reflecting on actual recruitment practices, as a trial is underway is a 
fundamental part of the QRI and can provide a means of identifying and working through these trial-
specific issues.  Peer-to-peer interactions involving recruiters from different sites, as facilitated in 
OPTIMA prelim through group feedback sessions, can be particularly helpful for engaging with these 
hidden challenges and dissolving discomforts.   
OPTIMA prelim recruitment, as with many oncology trials, relied on multidisciplinary professional 
involvement.  MDT members collectively screened and identified potentially eligible patients.  Breast 
surgeons and specialist nurses then had the important role of setting patients’ expectations about 
adjuvant treatment prior to a full discussion about the study with the oncologist.  Some surgeons 
continued to prepare eligible patients for adjuvant chemotherapy during post-surgery consultations, 
possibly reflecting lack of awareness about the trial, or equipoise issues.  The importance of a 
collaborative approach to recruitment is well established, [26-28] particularly in oncology [29], as is 
the drive for more holistic team approaches to recruitment training [30-33]. Our findings from 
OPTIMA prelim support an ongoing need to focus training and support on team ownership of 
recruitment, especially with trials that span clinical disciplines.   
The study had several limitations. Site participation in interviews and audio-recording of 
consultations was optional and 9/25 sites participated. It is possible that participating sites 
represented more engaged clinicians/sites; nonetheless, it is notable that even these possibly more 
‘engaged’ sites encountered the recurring challenges reported in this paper.  It is anticipated that 
less engaged sites also encountered these issues, with possible other challenges not captured. Four 
of the 14 semi-structured interviews were conducted with TMG members: whilst valuable for 
providing insight into the motivation and expected conduct of the study, these interviewees may 
have skewed the findings, although the issues reported in this paper were reflective of the general, 
recurring issues that arose across the dataset.  
Conversely, strengths of the study included use of audio-recordings of real recruitment interactions 
to examine what actually happens during recruitment discussions (rather than rely solely on 
informants’ reported practices), and the triangulation of multiple methods to identify the key 
sources of recruitment difficulty.  This enabled a detailed and robust understanding of recruitment 
issues in a relatively short space of time, which allowed the trial team to develop and implement 
strategies to address issues as the trial was underway (rather than towards the end of an RCT, when 
it is often too late).  The integration of multiple methods and converging findings lends credibility to 
our core findings, although future research should build on this study to examine whether these 
novel insights are relevant in a wider array of RCTs.  Further research should also be invested into 
the best methods of overcoming the common challenges recruiters face, including the cost-
effectiveness of training and feedback interventions such as the QRI.  
Conclusion 
This is the first study to expose the challenges of negotiating ‘routine clinical practice’ with clinical 
trial recruitment, which is now a core aspect of practising clinicians’ roles.  The findings highlight the 
need to support clinicians to negotiate their clinical and research roles, particularly in the context of 
de-escalation cancer trials.  
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Appendix 1  
OPTIMA Prelim Study Design and History 
 
OPTIMA prelim was designed to demonstrate the feasibility of a large-scale UK-based RCT of multi 
-parameter assay (MPA) directed chemotherapy and to select a test to be used in that trial.  
OPTIMA prelim recruited women aged 40 or older with resected ER-positive, HER-2 negative 
breast cancer, who had either 1-9 involved axillary nodes or a tumour of at least 30mm size.  
Randomisation was on a 1:1 ratio to current management (chemotherapy followed by endocrine 
therapy) or to MPA directed treatment using Oncotype DX.  Those with a Recurrence Score of >25 
(defined by the manufacturer as “high risk”) received chemotherapy followed by endocrine 
therapy whilst those with a score ≤25 (“intermediate/low risk”) received endocrine therapy 
alone.  The trial was partially blinded, in that the randomised allocation was not disclosed to 
patients or the treating clinician.  However, blinding was not possible where patients were 
randomised to the test-directed arm and received a ‘no chemotherapy’ outcome.  The process of 
consent and Oncotype DX testing took approximately three weeks, but this short delay to 
treatment was not considered detrimental to a patient’s outcome. 
 
The first OPTIMA prelim participant was recruited in October 2012 and the study closed to 
recruitment in August 2014.  In total, 35 hospitals from 31 NHS trusts and health boards in 
England, Scotland and Wales participated.  Most recruitment took place before Oncotype DX 
testing was routinely available in the NHS.  NICE recommended the Oncotype DX test be made 
available to some patients with node negative disease in September 2013 [34].  However, it was 
only in April 2014 that the recommendation started to be implemented in England; it took longer 
in Wales and Scotland.  Although the Oncotype DX test had been available in private healthcare 
for some time, familiarity with the test would have been limited during most of the recruitment 
period.  
 
Trial outcomes included achieving recruitment of 300 patients within 2 years from the first site 
opening, recruitment of the final 150 patients within a 6-month period and a patient acceptance 
rate of at least 40%.  These outcomes were met on 3 June 2014 when at the time of database 
lock, 350 patients had consented to join the study and 313 had proceeded to randomisation.  
Reasons for non-randomisation included central confirmation of receptor status or Oncotype DX 
testing still in progress (n=15), ineligibility (n=15) [which included discrepant receptor status on 
central re-testing (n=12)] and pre-randomisation withdrawal by either patient or clinician (n=7).  
 
OPTIMA prelim also included an evaluation of alternative MPAs to determine which technology 
should be evaluated in the main trial[35, 36]. Prosigna was selected as the MPA for use in the 














OPTIMA study: guidance for recruiters, September 2013 
This document lists suggestions that may help recruiters during appointments.  You may wish to consider 
including some of these suggestions in your appointments, alongside your own individual approach and style of 
discussing the OPTIMA study with patients. 
- Patients often find it reassuring to hear a summary of their surgery/pathology results 
- It is helpful to mention the OPTIMA study briefly early on 
- It is helpful to recount how knowledge of breast cancer has evolved over past decade with a range of 
treatment options in their clinical situation, and emphasise how we are constantly trying to improve 
treatment: e.g. tailoring a treatment plan to individual patients and types of cancer. 
- The aim of the study is to find out whether a personalised decision about whether to have chemotherapy or 
not can be made safely and effectively using a test such as Oncotype DX. 
- All patients receive hormone therapy because this is known to prevent future recurrence. It has fewer side 
effects than chemotherapy. 
- Chemotherapy would usually also be given but recent research has indicated that many women with this 
type of breast cancer may not benefit from it.  
- Usually the decision about chemotherapy is based on the size and grade of the tumour and the number of 
lymph glands involved. However, these tests are not very sensitive. 
- Tests such as Oncotype DX have been developed to try to better predict who would benefit from 
chemotherapy and who could avoid having it, by providing better information about the nature of the 
tumour and how it is likely to behave. 
- Explain what chemotherapy entails and its side effects. You might want to use these words, adding the 
particular patient’s level of risk instead of ‘x’:   
“We would estimate that for a patient like you, there is an x% chance that the chemo will stop 
the cancer from coming back. This means that if there were 100 people treated with chemo, 
only x would benefit from it, but all are likely to experience the side effects.”  
- You might want to explain that as we currently do not know how to predict who will benefit from 
chemotherapy, most women are advised to have it even though we know many will not be able to benefit 
but will experience the side effects.   
- The aim of the OPTIMA study is to enable us to gain evidence to enable us to be better at targeting 
chemotherapy to women who will benefit from it, and help women who will not benefit from going through 
an unnecessary treatment with side effects.  
- Explain that the ODx test is used in the US and other countries, but is not yet recommended for use in the 
NHS. 
- In the OPTIMA study we want to include women with larger tumours and those that have spread to the 
lymph glands, as well as in those with smaller, more confined tumours - to evaluate how useful it can be. 
- It is good to mention that OPTIMA is a study funded by the National Institute for Health Research (the NHS 
funding body) and is being carried out around the UK. 
Starting the appointment 
 
Information provision: different types of breast cancer and individualised/personalised treatment 
 
Purpose and overview of OPTIMA 




- It is also important to explain that the doctors and nurses involved in the patient’s care have already 
discussed their specific case, and agreed that it would be appropriate to offer them the opportunity to take 
part in the trial.  They are suitable to receive either of the study’s two treatment options.  
- When you explain the study design, you might like to draw the treatment options (arms) on a piece of paper, 
or use a pre-prepared diagram – such as the one in the Patient Information Sheet.  
- Make sure you call the arms ‘treatment option 1’ and ‘treatment option 2’.  Try to avoid calling them 
‘standard’ or ‘experimental’   
- Explain that option 1 is what they would receive if they do not take part in OPTIMA – hormone therapy and 
chemotherapy.  Option 2 is determined by the Oncotype DX test – that a sample of the tumour tissue 
(already removed during surgery) will be tested and the result will determine whether they will be 
recommended to have chemotherapy in addition to hormone therapy. 
- You need to explain how they will be allocated to option 1 or option 2.  We have found, from previous trials, 
that an explanation something like this can work well:  
“All women who agree to take part in the OPTIMA study will be allocated to option 1 or option 
2 through a process called ‘randomisation’.  This means that you will be assigned to option 1 or 
option 2 by chance – that you cannot choose and your doctor cannot choose. This is so that the 
options can be compared fairly – that the two groups will contain similar numbers and will be 
as similar to each other in all other respects.   
- It is important to re-iterate that the patient is suitable to receive either of the study’s two treatment options, 
and that everyone will receive hormone therapy. Also that all patients will be followed up very carefully – 
every three months in the first year, and once a year after that.   
- It is also important to explain how and why the patient and doctor will not know whether the patient was 
allocated to option 1 or option 2.  We have found that the following can work well: 
“Neither you nor the doctors will be told whether you were in option 1 or 2. This is because we 
need to compare these two groups as fairly as possible.  Our results will be more reliable if no 
other factors influence us and we can be more confident that the patients and doctors are 
behaving the same ways if they do not know whether the patient is in option 1 or 2. There is 
one exception to this: if you went into the test group and were recommended not to have 
chemotherapy, we would know that this must be because you have had the test done, and 
came back not needing chemotherapy. Looking back at this diagram, we would know this, 
because all the other groups receive chemotherapy as well as hormone therapy.”  
 
 
- It is important to explain that patients taking part in OPTIMA will need to wait 3-4 weeks before starting 
treatment, regardless of whether they are in option 1 or option 2 because of the need to test the tissue in 
the special laboratory (use diagram). 
- It is even more important to reassure the patient that waiting this amount of time will NOT have any 
detrimental effects on their health or outcome. For most, the cancer will have been present for some time 
and so this short delay will not make any difference.  Chemotherapy will be booked for all patients 
immediately because it takes two weeks to organise. If they then do not need chemotherapy, it will be 
cancelled. 
- Reassure patient that they can take some time to consider whether they want to take part. Make sure they 
have the main OPTIMA information sheet. Advise them that can contact the research nurse [or whoever 
appropriate] if they have questions. 
- Explain audio recording; give QRS information sheet/consent form.  
Explaining the OPTIMA study 
 
Closing the appointment 
Explaining timing and follow up within OPTIMA 
 
